Abrezekimab

• Description:

  Abrezekimab (VR 942) is composed of CDP7766, leucine, and trehalose. Abrezekimab is a humanized antibody that targets human IL-13. Abrezekimab inhibits binding to IL-13Rα1 subunit. Abrezekimab can be used to study biological disorders associated with asthma and lung disease.

• Stability:

  ≥ 2 years

• Purity:

  >98% (HPLC)

• Molecular Formula:

  ——

• Notes:

  Research use only, not for human use.

• Receptor:

  IL Receptor

• CAS Number:

  2043952-59-4